Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of MS-275 and CXD101 on open chromatin regions of M-MDSCs [ATAC-seq]

ABSTRACT: Effect of MS-275 and CXD101 on open chromatin regions of M-MDSCs [ATAC-seq]

PROVIDER: PRJNA971504 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24506572_1.fastq.gz	Fastqsanger.gz
	SRR24506572_2.fastq.gz	Fastqsanger.gz
	SRR24506574_1.fastq.gz	Fastqsanger.gz
	SRR24506574_2.fastq.gz	Fastqsanger.gz
	SRR24506575_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Effect of MS-275 and CXD101 on open chromatin regions of M-MDSCs [ATAC-seq]

Project description:To elucidate the molecular mechanisms of HDAC1-3 inhibitors in inhibiting M-MDSCs, ATAC-seq analysis of M-MDSCs isolated from Hepa 1-6 tumor-bearing mice treated with MS-275 or CXD101 were performed.

2025-02-03 | GSE232265 | GEO

Effect of MS-275 and CXD101 on gene expression of M-MDSCs and PMN-MDSCs [RNA-Seq]

Project description:To elucidate the molecular mechanisms of HDAC1-3 inhibitors in inhibiting M-MDSCs, RNA-seq analysis of M-MDSCs and PMN-MDSCs isolated from Hepa 1-6 tumor-bearing mice treated with MS-275 or CXD101 were performed.

2025-02-03 | GSE232267 | GEO

Effect of MS-275 and CXD101 on MDSCs

Project description:Effect of MS-275 and CXD101 on MDSCs

| PRJNA971499 | ENA

Effect of MS-275 and CXD101 on gene expression of M-MDSCs and PMN-MDSCs [RNA-Seq]

Project description:Effect of MS-275 and CXD101 on gene expression of M-MDSCs and PMN-MDSCs [RNA-Seq]

| PRJNA971509 | ENA

MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas

Project description:Phase I trial to study the effectiveness of combining MS-275 with isotretinoin in treating patients who have metastatic or advanced solid tumors or lymphomas. MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Isotretinoin may help cancer cells develop into normal cells. MS-275 may increase the effectiveness of isotretinoin by making cancer cells more sensitive to the drug. MS-275 and isotretinoin may also stop the growth of solid tumors or lymphomas by stopping blood flow to the cancer. Combining MS-275 with isotretinoin may kill more cancer cells

| 2011932 | ecrin-mdr-crc

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Project description:RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma.

| 2006457 | ecrin-mdr-crc

Transcriptome analysis of mouse embryonic stem cells treated with MS-275

Project description:This study describes transcriptome profiling of mouse ES cells treated with MS-275. We included RNA-Seq of ds_cDNA synthesized from double poly(A) selected mRNA RNA-Seq profiling on mouse ES cells treated with MS-275

2014-03-28 | E-GEOD-45909 | biostudies-arrayexpress

Transcriptome analysis of mouse embryonic stem cells treated with MS-275

Project description:This study describes transcriptome profiling of mouse ES cells treated with MS-275. We included RNA-Seq of ds_cDNA synthesized from double poly(A) selected mRNA

2014-03-28 | GSE45909 | GEO

Inhibition of histone deacetylation by MS-275 alleviates colitis by activating the vitamin D receptor

Project description:BACKGROUND: Ulcerative colitis (UC) is a common chronic inflammatory bowel disease without curative treatment. METHODS: We conducted gene set enrichment analysis to explore potential therapeutic agent for UC. Human colon tissue samples were collected to test H3 acetylation in UC. Both in vivo and in vitro colitis models were constructed to verify the role and mechanism of H3 acetylation modification in UC. Intestine-specific vitamin D receptor (VDR)-/- mice and VD (vitamin D)-deficient diet-fed mice were used to explore downstream molecular mechanism accordingly. RESULTS: According to the Connectivity Map database, MS-275 (class I histone deacetylase inhibitor) was the top-ranked agent, indicating potential importance of histone acetylation in the pathogenesis of UC. We then found that histone H3 acetylation was significantly decreased in the colon epithelium of UC patients and negatively associated with disease severity. MS-275 treatment inhibited histone H3 deacetylation, and subsequently attenuated nuclear factor kappa B (NF-?B)-induced inflammation, reduced cellular apoptosis, maintained epithelial barrier function, and thereby reduced colitis activity in a mouse model of colitis. We also identified VDR to be a downstream effector of MS-275. The curative effect of MS-275 on colitis was abolished in VDR-/- mice and in VD-deficient diet-fed mice and VDR directly targeted p65. In UC patients, histone H3 acetylation, VDR and zonulin-1 expression showed similar downregulation patterns and were negatively associated with disease severity. CONCLUSION: We demonstrate that MS-275 inhibits histone deacetylation and alleviates colitis by ameliorating inflammation, reducing apoptosis and maintaining intestinal epithelial barrier via VDR, providing new strategies for UC treatment.

2020-09-23 | GSE138495 | GEO

Next-Generation Sequencing Supports Quantitative Analysis of Wild Type and Runx2+/- Calvarial Transcriptomes With or Without Administration of MS-275

Project description:Because insufficiency of the Runt-related transcription factor 2 (Runx2) limits skeletal growth, there is a great deal of effort to activate Runx2 for clinical use. In this study, we found that MS-275, the class I-specific HDAC inhibitor, activates Runx2 both transcriptionally and translationally. Therefore, we performed NGS analysis to gain accurate patterns of gene expression in mouse calvaria tissue through MS-275 administration. As a result, we could get insight that treatment of MS-275 increases genes related with osteoblast differentiation and cell proliferation, and decreases genes in field of causing apoptosis.

2017-09-24 | GSE87608 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data